The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to ...

Pharmacological options for sRV failure remain poorly defined. This study aims to investigate the tolerability and effects of sacubitril/valsartan on sRV failure in adult patients with sRV. Methods In ...

Myocardial remodelling, entailing cellular and molecular changes in the different components of the cardiac tissue in response to damage, underlies the morphological and structural changes leading to ...

Introduction： The efficacy of blood pressure (BP) reduction of Sacubitril/valsartan has been proved in hypertension patients, yet not in patients with acute ischemic stroke (AIS). We aimed to ...

Because the proposed generic drug accused of infringement was a “complex” of bonded valsartan ... sacubitril, the patentee Novartis needed to urge and had successfully urged that ...

For present purposes, the claims of the ‘659 Patent called for a pharmaceutical combination comprising valsartan and sacubitril “administered in combination” in about a 1:1 ratio.

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

On Tuesday, the Kansas City Chiefs revealed a first look at the uniforms they will wear in Super Bowl LIX, which features an iconic patch to commemorate the team’s third-consecutive appearance in the ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...